2 months ago
INSM
AnalystsJason ZemanskyJason Zemansky's Stock Forecasts
AnalystsJason Zemansky
Sectors:
Analyst Ranking
Top 9%
#449 out of 5279 analysts
Average Return
+22.24%
Win Rate
58%26 out of 45
Risk vs Reward
Poor
Good
Jason Zemansky's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Insmed IncINSM | +197.14% | $27.28 | $81.06 | 2024-02-22 - 2025-02-21 | Strong Buy |
Werewolf Therapeutics IncHOWL | +180.18% | $2.17 | $6.08 | 2023-03-22 - 2024-03-22 | Strong Buy |
Insmed IncINSM | +175.86% | $26.43 | $72.91 | 2023-09-05 - 2024-09-05 | Strong Buy |
Insmed IncINSM | +131.29% | $69.96 | $161.81 | 2024-10-08 - 2025-10-08 | Strong Buy |
Esperion Therapeutics IncESPR | +118.25% | $1.37 | $2.99 | 2023-06-14 - 2024-06-14 | Strong Buy |
Jason Zemansky Analyst Color
Get additional color on Jason Zemansky's coverage of popular stocks
7 months ago
INSM
a year ago
INSM
a year ago
INSM
2 years ago
INSM
2 years ago
TVTX
2 years ago
TVTX
2 years ago
SNDX
2 years ago
INSM
2 years ago
INSM
Jason Zemansky's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biomarin Pharmaceutical IncBMRN | 1 | Strong Buy | $80.00 | +60.61% | Maintains | 17 hours ago |
Rocket Pharmaceuticals IncRCKT | 6 | Strong Buy | $9.00 | +208.22% | Maintains | 2 months ago |
Insmed IncINSM | 12 | Strong Buy | $213.00 | +98.31% | Maintains | 2 months ago |
Ligand Pharmaceuticals IncLGND | 1 | Strong Buy | $244.00 | +17.43% | Initiates Coverage On | 2 months ago |
Eikon Therapeutics IncEIKN | 1 | Strong Buy | $34.00 | +219.55% | Initiates Coverage On | 3 months ago |
Inhibikase Therapeutics IncIKT | 1 | Strong Buy | $6.00 | +282.17% | Initiates Coverage On | 4 months ago |
Keros Therapeutics IncKROS | 3 | Hold | $19.00 | +91.73% | Maintains | 6 months ago |
Arcus Biosciences IncRCUS | 6 | Hold | $26.00 | +14.29% | Maintains | 6 months ago |
Werewolf Therapeutics IncHOWL | 6 | Strong Buy | $7.00 | +1,535.51% | Maintains | 6 months ago |
Cytokinetics IncCYTK | 5 | Hold | $56.00 | -26.75% | Maintains | 8 months ago |
Travere Therapeutics IncTVTX | 4 | Strong Buy | $31.00 | N/A | Maintains | a year ago |
Kura Oncology IncKURA | 2 | Strong Buy | $29.00 | N/A | Maintains | a year ago |
Syndax Pharmaceuticals IncSNDX | 3 | Strong Buy | $31.00 | N/A | Maintains | 2 years ago |
Esperion Therapeutics IncESPR | 5 | Sell | $2.50 | N/A | Downgrades | 2 years ago |
Kalaris Therapeutics IncKLRS | 2 | Sell | $23.00 | N/A | Downgrades | 2 years ago |
Onkure Therapeutics IncOKUR | 1 | Strong Buy | $230.00 | N/A | Initiates Coverage On | 3 years ago |
Q32 Bio IncQTTB | 1 | Strong Buy | $162.00 | N/A | Maintains | 4 years ago |
Allakos IncALLK | 1 | Strong Buy | $155.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.